The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Bridge | Alive

Total Raised


Last Raised

$21.68M | 4 mos ago

About iN Therapeutics

iN Therapeutics is a biotechnology company specializing in new ion channel drug development.

iN Therapeutics Headquarter Location

South Korea

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing iN Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

iN Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest iN Therapeutics News

iN Therapeutics raises ₩26 billion in bridge capital to develop new drugs

Feb 7, 2022

iN Therapeutics raises ₩26 billion in bridge capital to develop new drugs 바로가기 기자명 Kim Chan-hyuk 닫기 Daewoong Pharmaceutical’s subsidiary iN Therapeutics said it raised 26 billion won ($21.6 million) bridge capital for new drug development. Last year, iN Therapeutics successfully attracted 14 billion won of Series A investment. The temporary funding came from new investors, Stic Ventures and Intervest, and existing investors that participated in the Series A investment -- Kiwoon Investment, E&Investment, Dayli Partners, Yuanta Investment, Aju IB Investment, Shinhan Capital, and Timefolio Asset Management. iN Therapeutics is testing iN1011-N17, an investigational non-narcotic drug for osteoarthritis pain, in a phase 1 study in Australia and preparing a phase 2 trial in Europe. iN Therapeutics plans to use the bridge capital to complete the phase 2 study in Europe and license out the drug to a multinational pharmaceutical company. The company will also speed up research on eight pipelines, including hearing loss treatment and brain disease therapy. iN Therapeutics is eyeing an initial public offering (IPO) in 2025. “We have successfully held the first Ion Channel Neuroscience Symposium, becoming a leader in neuroscience research,” iN Therapeutics CEO Park Chong-deok said. He said that the company was in talks with multiple global drugmakers to discuss technology transfer regarding the development of the non-narcotic osteoarthritis pain reliever. Park vowed to develop the new drug successfully and make it a global blockbuster drug.

  • What is iN Therapeutics's latest funding round?

    iN Therapeutics's latest funding round is Bridge.

  • How much did iN Therapeutics raise?

    iN Therapeutics raised a total of $34.19M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.